Throughout the last three months, 12 analysts have evaluated Halozyme Therapeutics (NASDAQ:HALO), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 2 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 4 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $55.0, a high estimate of $71.00, and a low estimate of $50.00. Witnessing a positive shift, the current average has risen by 1.63% from the previous average price target of $54.12.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts...
Login or create a forever free account to read this news
Sign up/Log in